Literature DB >> 15099288

Role of protease-activated and ADP receptor subtypes in thrombin generation on human platelets.

R T Dorsam1, M Tuluc, S P Kunapuli.   

Abstract

The activated platelet surface serves as an integral part of the prothrombinase complex upon activation by potent platelet agonists such as thrombin and collagen. We determined the receptor specificity through which thrombin was enhancing collagen-induced thrombin generation. Whereas SFLLRN or AYPGKF alone produced minimal thrombin generation or phosphatidylserine exposure through protease activated receptor (PAR) stimulation, they caused a leftward shift in the collagen-induced thrombin generation dose-response curve. Although SFLLRN or AYPGKF potentiated collagen-induced thrombin generation, neither of them potentiated to the same extent as thrombin. However, SFLLRN and AYPGKF together potentiated collagen-induced thrombin generation to the same extent as thrombin. We conclude that thrombin mediates its procoagulant activity through activation of both PAR1 and PAR4 receptors. Similarly, neither PAR1 nor PAR4 stimulation alone mimicked the annexin V-binding response caused by thrombin stimulation. The combination of PAR activating peptides caused minimal increases in annexin V binding, but caused significant thrombin generation, suggesting that events other than phosphatidylserine exposure may play a role in platelet prothrombinase complex formation. We also investigated the ability of ADP to potentiate agonist-induced thrombin generation. Whereas P2Y(1) antagonism did not affect collagen or thrombin-induced thrombin generation, P2Y(12) antagonism did decrease both collagen- and thrombin-induced thrombin generation, suggesting that ADP potentiates thrombin generation primarily through the P2Y(12) receptor. Collectively, these results suggest that stimulation of both the PAR1 and PAR4 receptors are necessary for thrombin-induced procoagulant activity, and that the P2Y(12) receptor, but not the P2Y(1) receptor, is responsible for the potentiation of agonist-induced platelet procoagulant activity.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15099288     DOI: 10.1111/j.1538-7836.2004.00692.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  12 in total

Review 1.  PAR-1 antagonists: current state of evidence.

Authors:  Saurav Chatterjee; Abhishek Sharma; Debabrata Mukherjee
Journal:  J Thromb Thrombolysis       Date:  2013-01       Impact factor: 2.300

2.  The variability of platelet response to aspirin and clopidogrel: revisiting the Caprie, Cure, Credo, and Match trials.

Authors:  Robert I Myers
Journal:  Proc (Bayl Univ Med Cent)       Date:  2005-10

Review 3.  Antiplatelet drug 'resistance'. Part 2: laboratory resistance to antiplatelet drugs-fact or artifact?

Authors:  Diana A Gorog; Joseph M Sweeny; Valentin Fuster
Journal:  Nat Rev Cardiol       Date:  2009-04-14       Impact factor: 32.419

4.  PAR4, but not PAR1, signals human platelet aggregation via Ca2+ mobilization and synergistic P2Y12 receptor activation.

Authors:  Michael Holinstat; Bryan Voss; Matthew L Bilodeau; Joseph N McLaughlin; John Cleator; Heidi E Hamm
Journal:  J Biol Chem       Date:  2006-07-12       Impact factor: 5.157

5.  Enhanced potency of prasugrel on protease-activated receptors following bivalirudin treatment for PCI as compared to clopidogrel.

Authors:  Carey Kimmelstiel; Ryan Stevenson; Nga Nguyen; Layla Van Doren; Ping Zhang; James Perkins; Navin K Kapur; Andrew Weintraub; Vilma Castaneda; Athan Kuliopulos; Lidija Covic
Journal:  Thromb Res       Date:  2019-02-13       Impact factor: 3.944

6.  Bivalirudin is a dual inhibitor of thrombin and collagen-dependent platelet activation in patients undergoing percutaneous coronary intervention.

Authors:  Carey Kimmelstiel; Ping Zhang; Navin K Kapur; Andrew Weintraub; Barath Krishnamurthy; Vilma Castaneda; Lidija Covic; Athan Kuliopulos
Journal:  Circ Cardiovasc Interv       Date:  2011-03-01       Impact factor: 6.546

7.  Activation of protease-activated receptors 3 and 4 accelerates tissue factor-induced thrombin generation on the surface of vascular smooth muscle cells.

Authors:  Param Vidwan; Alokkumar Pathak; Samar Sheth; Jianhua Huang; Dougald M Monroe; George A Stouffer
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-10-07       Impact factor: 8.311

Review 8.  The Function and Regulation of Platelet P2Y12 Receptor.

Authors:  Xiaohua Li; Guoxing Zhang; Xia Cao
Journal:  Cardiovasc Drugs Ther       Date:  2021-07-28       Impact factor: 3.727

Review 9.  Proteinase-activated receptors (PARs) - focus on receptor-receptor-interactions and their physiological and pathophysiological impact.

Authors:  Frank Gieseler; Hendrik Ungefroren; Utz Settmacher; Morley D Hollenberg; Roland Kaufmann
Journal:  Cell Commun Signal       Date:  2013-11-11       Impact factor: 5.712

Review 10.  Unmet needs in the management of acute myocardial infarction: role of novel protease-activated receptor-1 antagonist vorapaxar.

Authors:  Jung Rae Cho; Fabiana Rollini; Francesco Franchi; Elisabetta Ferrante; Dominick J Angiolillo
Journal:  Vasc Health Risk Manag       Date:  2014-04-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.